F Estelle R Simons

Summary

Affiliation: University of Manitoba
Country: Canada

Publications

  1. ncbi Epinephrine (adrenaline) in the first-aid, out-of-hospital treatment of anaphylaxis
    F Estelle R Simons
    Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, University of Manitoba, 820 Sherbrook Street, Winnipeg, Manitoba R3A 1R9, Canada
    Novartis Found Symp 257:228-43; discussion 243-7, 276-85. 2004
  2. ncbi Emergency treatment of anaphylaxis
    F Estelle R Simons
    BMJ 336:1141-2. 2008
  3. ncbi Clinical pharmacology of new histamine H1 receptor antagonists
    F E Simons
    Faculty of Medicine, University of Manitoba, Winnipeg, Canada
    Clin Pharmacokinet 36:329-52. 1999
  4. ncbi Epinephrine auto-injectors: first-aid treatment still out of reach for many at risk of anaphylaxis in the community
    F Estelle R Simons
    Department of Pediatrics and Child Health, Canadian Institutes of Health Research National Training Program in Allergy and Asthma, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba
    Ann Allergy Asthma Immunol 102:403-9. 2009
  5. ncbi Hazards of unintentional injection of epinephrine from autoinjectors: a systematic review
    F Estelle R Simons
    Departments of Pediatrics and Child Health, and Immunology, CIHR National Training Program in Allergy and Asthma, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Ann Allergy Asthma Immunol 102:282-7. 2009
  6. ncbi H1-antihistaminic activity of cetirizine and fexofenadine in allergic children
    F Estelle R Simons
    John Buhler Research Center Allergy Laboratory, Faculty of Medicine, Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada
    Pediatr Allergy Immunol 14:207-11. 2003
  7. ncbi Safety of levocetirizine treatment in young atopic children: An 18-month study
    F Estelle R Simons
    Department of Pediatrics and Child Health, Canadian Institutes of Health Research National Training Program in Allergy and Asthma, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Pediatr Allergy Immunol 18:535-42. 2007
  8. ncbi 9. Anaphylaxis
    F Estelle R Simons
    Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, The Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    J Allergy Clin Immunol 121:S402-7; quiz S420. 2008
  9. ncbi Advances in H1-antihistamines
    F Estelle R Simons
    Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, and the Canadian Institutes of Health Research National Allergy, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
    N Engl J Med 351:2203-17. 2004
  10. ncbi Anaphylaxis: Recent advances in assessment and treatment
    F Estelle R Simons
    Department of Pediatrics, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    J Allergy Clin Immunol 124:625-36; quiz 637-8. 2009

Collaborators

Detail Information

Publications88

  1. ncbi Epinephrine (adrenaline) in the first-aid, out-of-hospital treatment of anaphylaxis
    F Estelle R Simons
    Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, University of Manitoba, 820 Sherbrook Street, Winnipeg, Manitoba R3A 1R9, Canada
    Novartis Found Symp 257:228-43; discussion 243-7, 276-85. 2004
    ..Additional fixed-dose formulations of epinephrine are needed to facilitate optimal first-aid dosing in patients of all ages and sizes...
  2. ncbi Emergency treatment of anaphylaxis
    F Estelle R Simons
    BMJ 336:1141-2. 2008
  3. ncbi Clinical pharmacology of new histamine H1 receptor antagonists
    F E Simons
    Faculty of Medicine, University of Manitoba, Winnipeg, Canada
    Clin Pharmacokinet 36:329-52. 1999
    ..The studies cited in this review provide the scientific foundation for using the new H1 antagonists with optimal effectiveness and safety...
  4. ncbi Epinephrine auto-injectors: first-aid treatment still out of reach for many at risk of anaphylaxis in the community
    F Estelle R Simons
    Department of Pediatrics and Child Health, Canadian Institutes of Health Research National Training Program in Allergy and Asthma, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba
    Ann Allergy Asthma Immunol 102:403-9. 2009
    ..15 mg of epinephrine were reported to be available in 43.6% of countries. Auto-injectors containing an infant dose were not available in any country. The cost of 1 auto-injector ranged from US $30 to US $110...
  5. ncbi Hazards of unintentional injection of epinephrine from autoinjectors: a systematic review
    F Estelle R Simons
    Departments of Pediatrics and Child Health, and Immunology, CIHR National Training Program in Allergy and Asthma, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Ann Allergy Asthma Immunol 102:282-7. 2009
    ..To ascertain the rate of occurrence of unintentional injections from epinephrine autoinjectors used in the first aid treatment of anaphylaxis and to provide information about the resulting needle stick injuries...
  6. ncbi H1-antihistaminic activity of cetirizine and fexofenadine in allergic children
    F Estelle R Simons
    John Buhler Research Center Allergy Laboratory, Faculty of Medicine, Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada
    Pediatr Allergy Immunol 14:207-11. 2003
    ..In children age 6-11 years, cetirizine 10 mg has a rapid onset of H1-antihistaminic activity, a 24-h duration of action, and greater H1-activity than fexofenadine 30 mg. Higher doses of fexofenadine should be tested in children...
  7. ncbi Safety of levocetirizine treatment in young atopic children: An 18-month study
    F Estelle R Simons
    Department of Pediatrics and Child Health, Canadian Institutes of Health Research National Training Program in Allergy and Asthma, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Pediatr Allergy Immunol 18:535-42. 2007
    ..The long-term safety of levocetirizine has been confirmed in young atopic children...
  8. ncbi 9. Anaphylaxis
    F Estelle R Simons
    Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, The Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    J Allergy Clin Immunol 121:S402-7; quiz S420. 2008
    ..Prompt injection of epinephrine is life-saving. H1-antihistamines and inhaled beta2-adrenergic agonists cannot be depended on to prevent fatality. Long-term risk reduction is an integral part of management...
  9. ncbi Advances in H1-antihistamines
    F Estelle R Simons
    Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, and the Canadian Institutes of Health Research National Allergy, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
    N Engl J Med 351:2203-17. 2004
  10. ncbi Anaphylaxis: Recent advances in assessment and treatment
    F Estelle R Simons
    Department of Pediatrics, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    J Allergy Clin Immunol 124:625-36; quiz 637-8. 2009
    ..Randomized controlled trials of the pharmacologic interventions used in an acute anaphylaxis episode are needed...
  11. ncbi H1-antihistamine treatment in young atopic children: effect on urticaria
    F Estelle R Simons
    Department of Pediatrics, Canadian Institutes of Health Research National Training Program in Allergy and Asthma, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Ann Allergy Asthma Immunol 99:261-6. 2007
    ..There are few published, randomized, double-masked, placebo-controlled, clinical trials of interventions for urticaria in the pediatric population...
  12. ncbi Anaphylaxis in infants: can recognition and management be improved?
    F Estelle R Simons
    Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, Canadian Institutes of Health Research National Training Program in Allergy and Asthma, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
    J Allergy Clin Immunol 120:537-40. 2007
  13. ncbi Risk assessment in anaphylaxis: current and future approaches
    F Estelle R Simons
    Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Canada, and Department of Respiratory Medicine, Brighton General Hospital, Belfast, UK
    J Allergy Clin Immunol 120:S2-24. 2007
    ....
  14. ncbi Anaphylaxis in the community: learning from the survivors
    F Estelle R Simons
    Department of Pediatrics and Child Health, CIHR National Training Program in Allergy and Asthma, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    J Allergy Clin Immunol 124:301-6. 2009
    ..Most studies of anaphylaxis in the community focus on persons at risk who might, or might not, have experienced anaphylaxis...
  15. ncbi The role of antihistamines in the new millennium
    F E Simons
    Children s Hospital, Winnipeg, Manitoba, Canada R3A 1S1
    Postgrad Med 106:7-11. 1999
    ..This review explores the pharmacologic properties of these agents, their roles in treating allergic disorders, their safety, and the avenues of future inquiry that might further define their therapeutic possibilities...
  16. ncbi Population pharmacokinetics of levocetirizine in very young children: the pediatricians' perspective
    F Estelle R Simons
    Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada
    Pediatr Allergy Immunol 16:97-103. 2005
    ..Compared with older patients, on a mg/kg basis, relatively higher doses may be needed, and twice-daily dosing may be necessary, as previously reported for the related racemic H1-antihistamine cetirizine...
  17. ncbi Anaphylaxis: evidence-based long-term risk reduction in the community
    F Estelle R Simons
    Department of Pediatrics and Child Health, Department of Immunology, Canadian Institutes of Health Research National Training Program in Allergy and Asthma, University of Manitoba, 820 Sherbrook Street, Winnipeg, MB, R3A 1R9, Canada
    Immunol Allergy Clin North Am 27:231-48, vi-vii. 2007
    ..Anaphylaxis education should involve not only at-risk individuals and their families, but also health care professionals and the general public...
  18. ncbi Anaphylaxis, killer allergy: long-term management in the community
    F Estelle R Simons
    Department of Pediatrics and Child Health, Faculty of Medicine, The University of Manitoba, Canada
    J Allergy Clin Immunol 117:367-77. 2006
    ..Further development of an optimal diagnostic test for anaphylaxis and of tests and algorithms to predict future risk and prevent fatality are urgently needed...
  19. ncbi Pharmacologic treatment of anaphylaxis: can the evidence base be strengthened?
    F Estelle R Simons
    Department of Pediatrics and Child Health, Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Curr Opin Allergy Clin Immunol 10:384-93. 2010
    ..To evaluate the evidence base for the pharmacologic treatment of anaphylaxis...
  20. ncbi Epinephrine (adrenaline) in anaphylaxis
    F Estelle R Simons
    Department of Pediatrics and Child Health, Department of Immunology, Faculty of Medicine, Winnipeg, Man, Canada
    Chem Immunol Allergy 95:211-22. 2010
    ..These include epinephrine autoinjectors that are safer and easier to use, and epinephrine formulations that can be administered through non-invasive routes...
  21. ncbi Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years
    F Estelle R Simons
    Department of Pediatrics and Child Health, Department of Immunology, Canadian Institutes of Health Research National Training Program in Allergy and Asthma, Faculty of Medicine, The University of Mantoba, Manitoba, Canada
    J Allergy Clin Immunol 116:355-61. 2005
    ..Levocetirizine, the active enantiomer of cetirizine, is used in the treatment of allergic rhinitis and chronic urticaria in Europe. Its pharmacokinetics and pharmacodynamics have not yet been studied prospectively in school-age children...
  22. ncbi World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings
    F Estelle R Simons
    Department of Pediatrics and Child Health, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Ann Allergy Asthma Immunol 104:405-12. 2010
    ..The availability of anaphylaxis guidelines and of medications, supplies, and equipment for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings worldwide is unknown...
  23. ncbi Anaphylaxis
    F Estelle R Simons
    Department of Pediatrics and Child Health, Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    J Allergy Clin Immunol 125:S161-81. 2010
    ..Randomized controlled trials of pharmacologic agents, such as antihistamines and glucocorticoids, are needed to strengthen the evidence base for treatment of acute anaphylactic episodes...
  24. ncbi Voluntarily reported unintentional injections from epinephrine auto-injectors
    F Estelle R Simons
    Department of Pediatrics and Child Health, Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    J Allergy Clin Immunol 125:419-423.e4. 2010
    ..Epinephrine auto-injectors provide life-saving prehospital treatment for individuals experiencing anaphylaxis in community settings...
  25. ncbi Lack of worldwide availability of epinephrine autoinjectors for outpatients at risk of anaphylaxis
    F Estelle R Simons
    Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada
    Ann Allergy Asthma Immunol 94:534-8. 2005
    ..Epinephrine, the initial treatment of choice for anaphylaxis, is listed by the World Health Organization as an essential medication; however, the extent of its availability for outpatients is unknown...
  26. ncbi First-aid treatment of anaphylaxis to food: focus on epinephrine
    F Estelle R Simons
    Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada R3A 1R9
    J Allergy Clin Immunol 113:837-44. 2004
    ..The second issue could be addressed in part by development of alternative routes of epinephrine administration for the first-aid, out-of-hospital treatment of anaphylaxis...
  27. ncbi Fast-disintegrating sublingual tablets: effect of epinephrine load on tablet characteristics
    Mutasem M Rawas-Qalaji
    Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada
    AAPS PharmSciTech 7:E41. 2006
    ..Tablets with drug loads from 0% to 24% epinephrine can be formulated with hardness, disintegration times, and wetting times suitable for sublingual administration...
  28. ncbi Advances in mosquito allergy
    Zhikang Peng
    Department of Pediatrics and Child Health and Department of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada
    Curr Opin Allergy Clin Immunol 7:350-4. 2007
    ..Due to the lack of availability of mosquito salivary preparations for use in skin tests and in-vitro tests, allergic reactions to mosquito bites are under diagnosed and under treated...
  29. ncbi Regulation of the high affinity IgE receptor (Fc epsilonRI) in human neutrophils: role of seasonal allergen exposure and Th-2 cytokines
    Martin P Alphonse
    Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    PLoS ONE 3:e1921. 2008
    ....
  30. ncbi Epinephrine for the treatment of anaphylaxis: do all 40 mg sublingual epinephrine tablet formulations with similar in vitro characteristics have the same bioavailability?
    Mutasem M Rawas-Qalaji
    Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada
    Biopharm Drug Dispos 27:427-35. 2006
    ..05) than after epinephrine 0.3 mg i.m. These results suggest that the selection of excipients used in these tablet formulations can affect the bioavailability of sublingually administered epinephrine...
  31. ncbi Fast-disintegrating sublingual epinephrine tablets: effect of tablet dimensions on tablet characteristics
    Mutasem M Rawas Qalaji
    Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada
    Drug Dev Ind Pharm 33:523-30. 2007
    ..No difference in DT and WT was observed between concave and flat tablets. The 11/32'' and 10/32'' dies resulted in more ideal tablet dimensions for sublingual administration, but H must be maintained<4 kg to ensure rapid DT and WT...
  32. ncbi Hydroxyzine- and cetirizine-loaded liposomes: effect of duration of thin film hydration, freeze-thawing, and changing buffer pH on encapsulation and stability
    Abeer A W Elzainy
    Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada
    Drug Dev Ind Pharm 31:281-91. 2005
    ..1 degrees C. The effect of changing the buffer pH from 5.5 to 7.0, and from 5.0 to 6.5 on initial PETH and PEC, respectively, was minimal. After 24 months at l0 +/- 2 degrees C, pH had no effects on PETH; however, PEC of MLV decreased...
  33. ncbi Adult asthmatics display exaggerated IFNgamma responses to human metapneumovirus and respiratory syncytial virus
    Renée N Douville
    CIHR National Training Program in Allergy and Asthma Research, Department of Immunology, University of Manitoba, 603 Basic Medical Sciences Building, 730 William Ave, Winnipeg, MB R3E0W3, Canada
    Biochem Cell Biol 85:252-8. 2007
    ..This distinctive pattern of viral immunity may contribute to a worsening of asthma symptoms during respiratory virus infections...
  34. ncbi Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis
    Mutasem M Rawas-Qalaji
    Faculty of Pharmacy, University of Manitoba, Canada
    J Allergy Clin Immunol 117:398-403. 2006
    ..This novel, fast-disintegrating epinephrine tablet formulation for sublingual administration is a feasible alternative that warrants further development...
  35. ncbi Evidence for natural desensitization to mosquito salivary allergens: mosquito saliva specific IgE and IgG levels in children
    Zhikang Peng
    Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada
    Ann Allergy Asthma Immunol 93:553-6. 2004
    ..There are few epidemiologic data on the prevalence of mosquito allergy, although local reactions to mosquito bites are common...
  36. ncbi Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model
    Abeer A W Elzainy
    Faculty of Pharmacy, University of Manitoba, Winnipeg, Canada
    AAPS PharmSci 5:E28. 2003
    ..In this model, hydroxyzine from SUV and MLV had excellent topical H1-antihistaminic activity, and minimal systemic exposure occurred. Cetirizine formed in-vivo contributed to some of H1-antihistaminic activity...
  37. ncbi Is epinephrine administration by sublingual tablet feasible for the first-aid treatment of anaphylaxis? A proof-of-concept study
    Xiaochen Gu
    Assistant Professor, Division of Pharmaceutical Sciences, Faculty of Pharmacy, University of Manitoba, Canada R3T 2N2
    Biopharm Drug Dispos 23:213-6. 2002
    ..DEFINITIONS: HPLC-high performance liquid chromatography; EC - electrochemical detection; C(max) - maximum plasma epinephrine concentration after dosing; t(max) - time of maximum plasma epinephrine concentration...
  38. ncbi Cetirizine from topical phosphatidylcholine liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model
    Abeer A W Elzainy
    Faculty of Pharmacy, University of Manitoba, Winnipeg, Canada
    Biopharm Drug Dispos 25:359-66. 2004
    ..05. In this model, cetirizine from both SUV and MLV had excellent topical H(1)-antihistaminic effects, while systemic exposure to cetirizine from SUV was reduced...
  39. ncbi Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice
    Yanbing Ma
    Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada
    Am J Respir Crit Care Med 176:439-45. 2007
    ....
  40. ncbi Cetirizine from topical phosphatidylcholine-hydrogenated liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model
    Abeer A W Elzainy
    Faculty of Pharmacy, University of Manitoba, Winnipeg, Canada
    AAPS J 6:e18. 2004
    ..2 +/- 42.3 ng x hr/mL) were lower than from GB (AUC of 248.3 +/- 34.6 ng.hr/mL). In this model, cetirizine from MLV had excellent topical H(1)-antihistamine activity, while systemic exposure was reduced, compared with cetirizine from GB...
  41. ncbi Inhaled corticosteroids in childhood asthma: Income differences in use
    Anita L Kozyrskyj
    Department of Community Health Sciences, Manitoba Centre for Health Policy, Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada
    Pediatr Pulmonol 36:241-7. 2003
    ..In conclusion, a socioeconomic gradient in the use of inhaled corticosteroids prescriptions can be found among children with universal access to healthcare and drug insurance...
  42. ncbi Anaphylaxis pathogenesis and treatment
    F Estelle R Simons
    University of Manitoba, Winnipeg, MB, Canada
    Allergy 66:31-4. 2011
    ....
  43. ncbi Epinephrine fails to hasten hemodynamic recovery in fully developed canine anaphylactic shock
    Edgar Bautista
    Section of Respirology, University of Manitoba, Winnipeg, Man, Canada
    Int Arch Allergy Immunol 128:151-64. 2002
    ..Earlier administration of Epi, before maximal hypotension occurs, may produce a more beneficial effect...
  44. ncbi Clinical pharmacology of H1-antihistamines in the skin
    F Estelle R Simons
    Department of Pediatrics and Child Health, Faculty of Medicine, University of Manitoba, Canada
    J Allergy Clin Immunol 110:777-83. 2002
    ..CONCLUSIONS: In skin disorders for which H(1)-antihistamines are recommended, these results support the use of fexofenadine or loratadine, and they indicate the need for reexamination of the use of chlorpheniramine...
  45. ncbi Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA
    F Estelle R Simons
    Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, University of Manitoba, 820 Sherbrook Street, Winnipeg, Manitoba, Canada R3A 1R9
    J Allergy Clin Immunol 113:1144-51. 2004
    ..This novel approach has the potential for immune redirection in human immediate hypersensitivity diseases...
  46. ncbi Epinephrine and its use in anaphylaxis: current issues
    Keith J Simons
    Faculty of Pharmacy and Department of Pediatrics and Child Health, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Curr Opin Allergy Clin Immunol 10:354-61. 2010
    ..Here, we examine the evidence base for its primary role in the treatment of anaphylaxis episodes in community settings...
  47. ncbi Human subjects without peanut allergy demonstrate T cell-dependent, TH2-biased, peanut-specific cytokine and chemokine responses independent of TH1 expression
    Tina B Thottingal
    Department of Immunology, University of Manitoba, Winnipeg, Canada
    J Allergy Clin Immunol 118:905-14. 2006
    ..CLINICAL IMPLICATIONS: The continuum of responses between individuals with negative and individuals with positive skin test results, rather than TH1 versus TH2 bias, might be important in peanut allergy...
  48. ncbi Quandaries in prescribing an emergency action plan and self-injectable epinephrine for first-aid management of anaphylaxis in the community
    Scott H Sicherer
    Division of Allergy Immunology, University of Manitoba, Winnipeg, Canada
    J Allergy Clin Immunol 115:575-83. 2005
    ..Additional studies of the recognition and treatment of anaphylaxis in the community are needed to develop comprehensive, evidence-based recommendations for its management in this setting...
  49. ncbi Allergic humans are hyporesponsive to a CXCR3 ligand-mediated Th1 immunity-promoting loop
    J Darren Campbell
    CIHR National Training Program in Allergy and Asthma Research, Department of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada
    FASEB J 18:329-31. 2004
    ....
  50. ncbi Simultaneous analysis of the H1-antihistamine acrivastine and the decongestant pseudoephedrine hydrochloride by high-performance liquid chromatography
    Xiaochen Gu
    Faculty of Pharmacy, University of Manitoba, 50 Sifton Road, Winnipeg, Manitoba, Canada R3T 2N2
    J Pharm Biomed Anal 37:663-7. 2005
    ..This method was used to assay various samples from studies of the commercial preparation Semprex-D capsules. The method was found to be accurate, specific, selective, rapid, and versatile for use in routine quality control analyses...
  51. ncbi H1-antihistamines in children
    F Estelle R Simons
    University of Manitoba, Winnipeg, Manitoba, Canada
    Clin Allergy Immunol 17:437-64. 2002
    ..Pediatric formulations of the new H1-antagonists cetirizine, fexofenadine, and loratadine are now available for use...
  52. ncbi Are plasma IL-10 levels a useful marker of human clinical tolerance in peanut allergy?
    Larisa C Lotoski
    Department of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada
    PLoS ONE 5:e11192. 2010
    ..Recent studies suggest that constitutively elevated global serum levels of IL-10, a cytokine that down-regulates both Th1 and Th2 cytokine production, may be useful in identifying human clinical tolerance to foods...
  53. ncbi Reovirus serotypes elicit distinctive patterns of recall immunity in humans
    Renée N Douville
    Department of Immunology, University of Manitoba, Basic Medical Sciences Bldg, 730 William Ave, Winnipeg, Manitoba, Canada R3E 0W3
    J Virol 82:7515-23. 2008
    ..Thus, despite extensive genetic and morphological similarities between reovirus serotypes, the nature and intensity of the human recall responses as well as the control mechanisms regulating them are clearly distinct...
  54. ncbi An electronic tongue: evaluation of the masking efficacy of sweetening and/or flavoring agents on the bitter taste of epinephrine
    Ousama Rachid
    Faculty of Pharmacy, University of Manitoba, Apotex Centre, 750 McDermot Avenue, Winnipeg, Manitoba, R3E 0T5, Canada
    AAPS PharmSciTech 11:550-7. 2010
    ..3 (not detected). Using the e-Tongue, the incorporation of a variety of sweetening and/or flavoring NMIs into a SL tablet of E could be shown to mask its bitter taste by up to 80%. These results should be confirmed by in vivo studies...
  55. ncbi Histamine and H(1)-antihistamines: Celebrating a century of progress
    F Estelle R Simons
    Department of Pediatrics and Child Health and the Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    J Allergy Clin Immunol 128:1139-1150.e4. 2011
    ..Additional novel compounds being studied include H(4)-antihistamines with anti-inflammatory effects in allergic rhinitis, atopic dermatitis, and other diseases. Antihistamines have a storied past and a promising future...
  56. ncbi Evaluation and comparison of five matrix excipients for the controlled release of acrivastine and pseudoephedrine
    Xiaochen Gu
    Faculty of Pharmacy, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
    Drug Dev Ind Pharm 30:1009-17. 2004
    ..A combined lipid-based Compritol and hydrophilic Methocel produced optimal controlled drug release for longer than 8 hours for both acrivastine and pseudoephedrine...
  57. ncbi EpiPen Jr versus EpiPen in young children weighing 15 to 30 kg at risk for anaphylaxis
    F Estelle R Simons
    Department of Pediatrics and Child Health, Faculty of Medicine, University of Manitoba, Canada
    J Allergy Clin Immunol 109:171-5. 2002
    ..For the out-of-hospital treatment of anaphylaxis, additional premeasured, fixed doses of epinephrine would facilitate more precise dosing in young children...
  58. ncbi Immune responses to mosquito saliva in 14 individuals with acute systemic allergic reactions to mosquito bites
    Zhikang Peng
    Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, University of Manitoba, 532 714 McDermot Avenue, Winnipeg, Manitoba, Canada R3E 3P4
    J Allergy Clin Immunol 114:1189-94. 2004
    ..Mosquito bite-induced acute systemic allergic reactions are an increasing clinical concern and have not been optimally characterized immunologically...
  59. ncbi Safety of cetirizine in infants 6 to 11 months of age: a randomized, double-blind, placebo-controlled study
    F Estelle R Simons
    Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, Faculty of Medicine, The University of Manitoba, 820 Sherbrook Street, Winnipeg, Manitoba, Canada R3A 1R9
    J Allergy Clin Immunol 111:1244-8. 2003
    ..Additional prospective, randomized, double-blind, placebo-controlled, long-term studies of cetirizine and other H(1)-antihistamines are needed in this population...
  60. ncbi Epinephrine dispensing patterns for an out-of-hospital population: a novel approach to studying the epidemiology of anaphylaxis
    F Estelle R Simons
    Manitoba Centre for Health Policy, University of Manitoba, 820 Sherbrook Street, Winnipeg, Manitoba, Canada R3A 1R9
    J Allergy Clin Immunol 110:647-51. 2002
    ..Using this approach, we provide evidence that anaphylaxis from all triggers peaks in early childhood and then gradually declines into old age...
  61. ncbi Dissolution testing of sublingual tablets: a novel in vitro method
    Ousama Rachid
    Faculty of Pharmacy, University of Manitoba, Apotex Centre, Winnipeg, Canada
    AAPS PharmSciTech 12:544-52. 2011
    ..05). Results reflecting the dissolution of rapidly disintegrating tablets using simulated SL conditions were obtained using the novel in vitro dissolution method...
  62. ncbi Comparative pharmacology of H1 antihistamines: clinical relevance
    F Estelle R Simons
    Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Am J Med 113:38S-46S. 2002
    ..Many H1 antihistamines are currently available for use. Clinical pharmacology studies help physicians to select the best H1 antihistamines for their patients...
  63. ncbi Mosquito allergy: immune mechanisms and recombinant salivary allergens
    Zhikang Peng
    Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Canada
    Int Arch Allergy Immunol 133:198-209. 2004
    ..These recombinant allergens will significantly improve diagnosis of mosquito allergy and eventually will also improve specific immunotherapy for patients with systemic reactions to mosquito bites...
  64. ncbi Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis
    F Estelle R Simons
    Section of Allergy and Clinical Immunology, Department of Pedia-trics and Child Health, University of Manitoba, Winnipeg, Canada
    J Allergy Clin Immunol 111:617-22. 2003
    ..No clinically significant changes in QTc intervals were observed. CONCLUSIONS: Desloratadine rapidly and safely reduced the symptoms of perennial allergic rhinitis, and its efficacy did not diminish during 4 weeks of treatment...
  65. ncbi H1-Antihistamines: more relevant than ever in the treatment of allergic disorders
    F Estelle R Simons
    Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Canada
    J Allergy Clin Immunol 112:S42-52. 2003
    ..Second-generation H(1)-antihistamines are more relevant than ever in the treatment of allergic disorders...
  66. ncbi IgE modulates neutrophil survival in asthma: role of mitochondrial pathway
    Arash Shoja Saffar
    Department of Immunology, Canadian Institutes of Health Research National Training Program in Allergy and Asthma Research, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    J Immunol 178:2535-41. 2007
    ..Taken together, our results indicate that in vitro IgE can delay programmed cell death of neutrophils from allergic asthmatics and this may possibly contribute to neutrophilic inflammation in atopic asthma...
  67. ncbi Development of a drug treatment-based severity measure in childhood asthma
    Anita L Kozyrskyj
    Department of Community Health Sciences, Manitoba Centre for Health Policy, Faculty of Medicine, Winnipeg, Canada
    J Asthma 39:421-8. 2002
    ..These findings show that a drug treatment-based severity measure in childhood asthma, which can be applied to prescription data, has good reliability and validity, and is responsive to changes in asthma severity over time...
  68. ncbi Systemic chemokine and chemokine receptor responses are divergent in allergic versus non-allergic humans
    J Darren Campbell
    Departments of Immunology, Basic Medical Sciences Building, 730 William Avenue, Winnipeg, Manitoba R3E 0W3, Canada
    Int Immunol 14:1255-62. 2002
    ....
  69. ncbi Clinical pharmacology of H1-antihistamines
    F Estelle R Simons
    University of Manitoba, Winnipeg, Manitoba, Canada
    Clin Allergy Immunol 17:141-78. 2002
  70. ncbi American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis
    Linda Cox
    Department of Clinical Medicine, Nova Southeastern University College of Osteopathic Medicine, Davie, FL 33334, USA
    J Allergy Clin Immunol 120:1373-7. 2007
    ..The OJTF report provides recommendations for physicians who prescribe Xolair (omalizumab) on (1) the suggested wait periods after administration and (2) patient education regarding anaphylaxis...
  71. ncbi Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report
    Cezmi A Akdis
    Swiss Institute of Allergy and Asthma Research, Davos
    J Allergy Clin Immunol 118:152-69. 2006
    ..The consensus report is part of the PRACTALL initiative, which is endorsed by both academies...
  72. ncbi Self-injectable epinephrine for first-aid management of anaphylaxis
    Scott H Sicherer
    Pediatrics 119:638-46. 2007
    ....
  73. ncbi Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma
    Bradley E Chipps
    Capital Allergy and Respiratory Disease Center, Sacramento, CA 95819, USA
    J Allergy Clin Immunol 119:1156-63. 2007
    ..Young patients with severe or difficult-to-treat asthma are an understudied population...
  74. ncbi Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium
    Hugh A Sampson
    Division of Pediatric Allergy and Immunology, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    J Allergy Clin Immunol 117:391-7. 2006
    ....
  75. ncbi Histamine receptors are hot in immunopharmacology
    Cezmi A Akdis
    Swiss Institute of Allergy and Asthma Research SIAF, Obere Strasse 22, CH 7270 Davos, Switzerland
    Eur J Pharmacol 533:69-76. 2006
    ..This article highlights recent discoveries in histamine immunobiology and discusses their relevance in allergic inflammation...
  76. ncbi Relevance of H1-receptor occupancy to H1-antihistamine dosing in children
    Keith J Simons
    J Allergy Clin Immunol 119:1551-4. 2007
  77. ncbi Apparent lack of response to epinephrine in anaphylaxis
    F Estelle R Simons
    J Allergy Clin Immunol 115:640; author reply 640-1. 2005
  78. ncbi Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis
    Ulrich Wahn
    Department of Pediatric Pneumology and Immunology, University Children's Hospital, Berlin, Germany
    J Allergy Clin Immunol 111:763-9. 2003
    ..CONCLUSION: The efficacy and safety of the H(1)-antihistamine fexofenadine has been confirmed in this multicenter, multinational study of children aged 6 to 11 years with seasonal allergic rhinitis...
  79. ncbi Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis
    Peter Vadas
    Department of Medicine, Division of Allergy and Clinical Immunology, St Michael s Hospital, Toronto, ON, Canada
    N Engl J Med 358:28-35. 2008
    ..The roles of PAF and PAF acetylhydrolase, the enzyme that inactivates PAF, in anaphylaxis in humans have not been reported...
  80. ncbi Concerns about intranasal corticosteroids for over-the-counter use: position statement of the Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology
    Leonard Bielory
    Department of Medicine, UMDNJ-New Jersey Medical School, Newark, USA
    Ann Allergy Asthma Immunol 96:514-25. 2006
    ..Thus, as stated, we recommend that intranasal corticosteroids remain prescription-only drugs...
  81. ncbi Diphenhydramine in infants
    F Estelle R Simons
    Arch Pediatr Adolesc Med 161:105; author reply 105. 2007
  82. ncbi Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization
    S F Kemp
    Department of Medicine, The University of Mississippi Medical Center, Jackson, MS, USA
    Allergy 63:1061-70. 2008
    ..m. doses...
  83. ncbi Peanut allergy: recent advances
    F Estelle R Simons
    Pediatr Res 54:291-2. 2003
  84. ncbi Comparision of the mosquito saliva-capture enzyme-linked immunosorbent assay and the unicap test in the diagnosis of mosquito allergy
    Qiang Wang
    Ann Allergy Asthma Immunol 99:199-200. 2007
  85. ncbi Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA)
    Jean Bousquet
    Allergy 58:192-7. 2003
  86. ncbi Moving forward in pediatric allergy & immunology
    F Estelle R Simons
    Pediatr Allergy Immunol 14:243-5. 2003
  87. ncbi Mosquito saliva-specific IgE and IgG antibodies in 1059 blood donors
    Zhikang Peng
    J Allergy Clin Immunol 110:816-7. 2002
  88. ncbi H1-antihistamines and the central nervous system
    Michael J Welch
    Allergy and Asthma Medical Group and Research Center, University of California, San Diego, San Diego, California, USA
    Clin Allergy Immunol 17:337-88. 2002
    ....